JP2010507567A5 - - Google Patents

Download PDF

Info

Publication number
JP2010507567A5
JP2010507567A5 JP2009523960A JP2009523960A JP2010507567A5 JP 2010507567 A5 JP2010507567 A5 JP 2010507567A5 JP 2009523960 A JP2009523960 A JP 2009523960A JP 2009523960 A JP2009523960 A JP 2009523960A JP 2010507567 A5 JP2010507567 A5 JP 2010507567A5
Authority
JP
Japan
Prior art keywords
use according
pharmaceutically acceptable
cxcr4 inhibitor
acceptable salt
cxcr2 agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009523960A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010507567A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/075376 external-priority patent/WO2008019371A1/en
Publication of JP2010507567A publication Critical patent/JP2010507567A/ja
Publication of JP2010507567A5 publication Critical patent/JP2010507567A5/ja
Withdrawn legal-status Critical Current

Links

JP2009523960A 2006-08-07 2007-08-07 併用療法 Withdrawn JP2010507567A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83640906P 2006-08-07 2006-08-07
PCT/US2007/075376 WO2008019371A1 (en) 2006-08-07 2007-08-07 Combination therapy

Publications (2)

Publication Number Publication Date
JP2010507567A JP2010507567A (ja) 2010-03-11
JP2010507567A5 true JP2010507567A5 (https=) 2010-09-30

Family

ID=39033325

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009523960A Withdrawn JP2010507567A (ja) 2006-08-07 2007-08-07 併用療法

Country Status (12)

Country Link
US (1) US20100178271A1 (https=)
EP (1) EP2056853A1 (https=)
JP (1) JP2010507567A (https=)
CN (1) CN101500595A (https=)
AR (1) AR062271A1 (https=)
AU (1) AU2007281677A1 (https=)
BR (1) BRPI0715393A2 (https=)
CA (1) CA2659337A1 (https=)
IL (1) IL196559A0 (https=)
MX (1) MX2009001445A (https=)
RU (1) RU2009108289A (https=)
WO (1) WO2008019371A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008086426A2 (en) * 2007-01-09 2008-07-17 Cleveland Biolabs, Inc. Methods for increasing and mobilizing hematopoietic stem cells
EP2262494A2 (en) * 2008-02-29 2010-12-22 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of post-radiation tumor growth by an inhibitor of vasculogenesis
US10813917B2 (en) * 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
WO2011119738A2 (en) 2010-03-23 2011-09-29 The Johns Hopkins University Methods of treatment using stem cell mobilizers
US8546353B2 (en) 2010-05-06 2013-10-01 Glykos Finland Oy Compounds and combinations
EP2384759A1 (en) 2010-05-06 2011-11-09 Suomen Punainen Risti Veripalvelu Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells
ES2370986B1 (es) * 2010-06-08 2012-11-16 Institut Quimic De Sarria Cets Nuevos inhibidores de cxcr4 como agentes anti-vih
WO2012047339A2 (en) 2010-06-28 2012-04-12 The General Hospital Corporation Anti-cxcr4 as a sensitizer to cancer therapeutics
WO2012019168A2 (en) * 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
WO2012129073A2 (en) * 2011-03-18 2012-09-27 University Of Virginia Patent Foundation Compositions and methods for tissue engineering and cell based therapies
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
KR20140045411A (ko) 2011-05-16 2014-04-16 젠자임 코포레이션 Ｃｘｃｒ４ 길항제의 용도
EP2720690A4 (en) 2011-06-16 2014-12-31 Childrens Medical Center COMBINED CHEMICAL MODIFICATION OF SPHINGOSIN-1-PHOSPHATE (S1P) AND CXCR4 SIGNALING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND TRANSPLANT
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
KR102503695B1 (ko) * 2013-02-28 2023-02-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 줄기세포를 동원하기 위한 방법 및 조성물
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3302710A4 (en) * 2015-06-03 2019-02-20 The University of Queensland MOBILIZERS AND USE THEREOF
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
CN110035702A (zh) * 2016-10-24 2019-07-19 耶鲁大学 穿刺装置
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
AU2018358012A1 (en) 2017-11-03 2020-04-02 Roemer & Heigl Gmbh Extraction of stem cells from bone marrow niches
CN111712262A (zh) * 2017-12-06 2020-09-25 美真达治疗公司 用于动员造血干细胞和祖细胞的给药方案
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
WO2022101359A1 (en) 2020-11-12 2022-05-19 Roemer & Heigl Gmbh Reversible release of stem cells from bone marrow niches
WO2025224720A1 (en) 2024-04-24 2025-10-30 Biolinerx Ltd. Methods of selecting treatment regimen against solid tumors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
US6447766B1 (en) * 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
ES2210255T3 (es) * 1993-06-08 2004-07-01 Smithkline Beecham Corporation Metodos para mejorar la actividad biologica de quimiocinas.
DE4320478B4 (de) * 1993-06-21 2007-11-15 Robert Bosch Gmbh Fahrstabilitätsregler
GB9400411D0 (en) * 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6713052B1 (en) * 1995-10-24 2004-03-30 Human Genome Sciences, Inc. Method of mobilizing stem cells with chemokine β-8
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
AU2334301A (en) * 1999-12-17 2001-06-25 Anormed Inc. Chemokine receptor binding heterocyclic compounds
US6734191B2 (en) * 2000-09-15 2004-05-11 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
HK1052011A1 (zh) * 2000-09-15 2003-08-29 Anormed Inc. 趋化因子受体结合杂环化合物
DE60136476D1 (de) * 2000-09-29 2008-12-18 Anormed Inc -stickstoffhaltigen zyklischen polyaminen und deren verbindungen
US6853731B1 (en) * 2000-09-30 2005-02-08 Keen Personal Technologies, Inc. Digital video recorder employing a unique ID to interlock with encrypted video programs stored on a storage device
WO2002081727A2 (en) * 2001-04-03 2002-10-17 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
DK1411918T3 (da) * 2001-07-31 2012-04-23 Genzyme Global S A R L Fremgangsmåder til at mobilisere progenitor/stamceller
CN100463962C (zh) * 2001-12-07 2009-02-25 图尔金株式会社 嵌合蛋白质的表型筛选
WO2004091518A2 (en) * 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
JP4778420B2 (ja) * 2003-04-22 2011-09-21 アノーメッド インコーポレイティド 増強された有効性を有するケモカインレセプタ結合複素環式化合物
EP1708703A4 (en) * 2003-12-11 2008-04-09 Anormed Inc CHEMOKIN RECEPTOR BINDING COMPOUNDS

Similar Documents

Publication Publication Date Title
JP2010507567A5 (https=)
JP2009545620A5 (https=)
RU2009108289A (ru) Комбинированная терапия
Pusic et al. Update on clinical experience with AMD3100, an SDF-1/CXCL12–CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells
RU2009107030A (ru) Комбинированная терапия
EP4353818A3 (en) Compositions, articles of manufacture and methods related to dosing in cell therapy
JP2012526850A5 (https=)
CA2560058A1 (en) A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
JP2007529532A5 (https=)
KR102854375B1 (ko) 혈액 암을 위한 조합 치료법
CN106822905B (zh) 含Survivin抑制剂和IRE1抑制剂的药物及用途
MX2010010026A (es) Agente para tratar enfermedad.
JP2019503365A5 (https=)
JP2010501159A5 (https=)
JP2012067116A5 (https=)
NZ707377A (en) Combination therapy methods for treating proliferative diseases
MX358491B (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
JP2023541430A5 (https=)
JP2009545600A5 (https=)
JP2021046446A (ja) グルココルチコイド及びｅｄｏ−ｓ１０１を含む組合せ
MA56827B2 (fr) Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
JP2023012503A5 (https=)
JP2009506054A5 (https=)
JP2020524179A5 (https=)
JP2013540734A5 (https=)